| Literature DB >> 29778254 |
Anne C Moorman1, Loralee B Rupp2, Stuart C Gordon2, Yuna Zhong3, Jian Xing3, Mei Lu4, Joseph A Boscarino5, Mark A Schmidt6, Yihe G Daida7, Eyasu H Teshale3, Philip R Spradling3, Scott D Holmberg3.
Abstract
Chronic Hepatitis Cohort Study (CHeCS) publications using data from "real-world" patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%-3.5% per year during 2006-10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease. Published by Elsevier Inc.Entities:
Keywords: Cirrhosis; Comorbidities; Direct-acting antiviral; Hepatitis C; Mortality; Real-world cohort; Sustained viral response
Mesh：
Substances：
Year: 2018 PMID： 29778254 PMCID： PMC6211170 DOI： 10.1016/j.idc.2018.02.002
Source DB: PubMed Journal: Infect Dis Clin North Am ISSN： 0891-5520 Impact factor: 5.982